Please login to the form below

Not currently logged in
Email:
Password:

Keith Webber leaves FDA for Perrigo

Switches regulatory agency for biopharma company

Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process.

Perrigo will benefit from Webber's experience working with the US regulator, including most recently as acting director of the office of the FDA's pharmaceutical science in the Center for Drug Evaluation and Research (CDER), which over-the-counter and prescription drugs.

Prior to this, he oversaw regulation of generic medicines at the FDA as director of office of generic drug. This followed a period serving in several other leadership roles within the FDA.

The role marks a switch to the industry side of pharma for Webber, heading all the Perrigo's regulatory activities for both its consumer healthcare and prescription medicine business.

This includes holding responsibility for advancing the approval of drugs and providing guidance on regulatory strategy for products in development.

Perrigo's Chairman, president and CEO Joseph Papa commented that Webber “brings to us a wealth of strategic, scientific and regulatory experience from his years working with the FDA”.

27th September 2013

From: Sales, Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics